Verve Therapeutics Strikes Gene Editing Deal With Eli Lilly
By Will Feuer
Verve Therapeutics said it has struck an exclusive research collaboration with Eli Lilly focused on advancing Verve's preclinical in vivo gene-editing program targeting lipoprotein.
The company said elevated lipoprotein is a risk factor for atherosclerotic cardiovascular disease, ischemic stroke, thrombosis and aortic stenosis.
Under the terms of the deal, Verve will continue to advance the research and development of the lipoprotein program through phase one of clinical development. Lilly will then take over development, manufacturing and commercialization of the program.
Verve will receive $60 million through an upfront payment and equity investment from Lilly, which also will fund the research costs through phase one clinical trials.
Verve is eligible to receive up to $465 million in milestone payments and tiered sales royalties. Verve also can opt-in to co-fund and share margins globally on the lipoprotein program instead of receiving the milestones and royalties.
Verve Chief Executive Sekar Kathiresan said the deal will give the company cash runway into 2026.
Shares of Verve rose 2.8% in premarket trading.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
June 15, 2023 07:01 ET (11:01 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Stocks to Buy While They’re Trading at Big Discounts
-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
Should You Buy and Hold an Artificial Intelligence Portfolio?
-
3 Cheap and Dependable Dividend-Growth Stocks to Buy
-
The Best Bank Stocks to Buy
-
After Earnings, Is Roblox Stock a Buy, Sell, or Fairly Valued?
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?